Skip to main content
    A

    Abbott Laboratories (ABT)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $107.52
    -1.00 (-0.92%)

    Market Cap: $187.95B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Abbott Laboratories (ABT) Financials: Revenue, Profit and Cash Flow

    Updated Oct 21, 2026. Financial statements from company filings, amounts in US dollars.

    Abbott Laboratories reported revenue of $44.33B for the fiscal year ended Dec 31, 2025, up 5.7% from the year before. That year, net income was $6.52B with a net margin of 14.7%, operating cash flow was $9.57B and free cash flow was $7.39B. The quarter ended Sep 30, 2026 had revenue of $13.01B and net income of $920.00M.

    Revenue and Margins

    The operating margin was 18.2% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $20.85B, a compound annual rate of 8.7%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$44.33B+5.7%56.4%18.2%14.7%
    Dec 2024$41.95B+4.6%55.4%16.3%31.9%
    Dec 2023$40.11B-8.1%55.2%16.2%14.3%
    Dec 2022$43.65B+1.3%56.1%19.2%15.9%
    Dec 2021$43.08B+24.5%57.0%19.6%16.4%
    Dec 2020$34.61B+8.5%56.6%15.5%13.0%
    Dec 2019$31.90B+4.3%58.5%14.2%11.6%
    Dec 2018$30.58B+11.6%58.4%11.9%7.7%
    Dec 2017$27.39B+31.3%54.7%5.7%1.7%
    Dec 2016$20.85BN/A56.4%14.5%6.7%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income fell 51.3% from the year before. In the quarter ended Sep 2026, net income fell 43.9% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$44.33B$41.95B$40.11B$43.65B$43.08B$34.61B$31.90B$30.58B$27.39B$20.85B
    Cost of revenue$19.32B$18.71B$17.98B$19.14B$18.54B$15.00B$13.23B$12.71B$12.41B$9.09B
    Gross profit$25.01B$23.24B$22.13B$24.51B$24.54B$19.61B$18.67B$17.87B$14.98B$11.76B
    Research and development$2.94B$2.84B$2.74B$2.89B$2.74B$2.42B$2.44B$2.30B$2.26B$1.45B
    Operating income$8.05B$6.83B$6.48B$8.36B$8.43B$5.36B$4.53B$3.65B$1.56B$3.03B
    Net income$6.52B$13.40B$5.72B$6.93B$7.07B$4.50B$3.69B$2.37B$477.00M$1.40B
    EBITDA$11.77B$10.45B$10.16B$11.95B$12.24B$8.79B$7.73B$7.07B$6.94B$3.26B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$13.01B$12.59B$11.16B$11.46B$11.37B$11.14B$10.36B$10.97B$10.63B$10.38B$9.96B$10.24B
    Gross profit$7.38B$7.27B$6.27B$6.54B$6.29B$6.29B$5.89B$6.03B$5.94B$5.77B$5.50B$5.68B
    Operating income$1.36B$1.69B$1.34B$2.25B$2.06B$2.05B$1.69B$1.91B$1.86B$1.67B$1.39B$1.78B
    Net income$920.00M$928.00M$1.08B$1.78B$1.64B$1.78B$1.32B$9.23B$1.65B$1.30B$1.23B$1.59B
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $12.93B exceeded cash and equivalents by $4.41B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$86.71B$81.41B$73.21B$74.44B$75.20B$72.55B$67.89B$67.17B$76.25B$52.67B
    Current assets$26.00B$23.66B$22.67B$25.22B$24.24B$20.44B$15.67B$14.63B$20.15B$26.78B
    Cash and equivalents$8.52B$7.62B$6.90B$9.88B$9.80B$6.84B$3.86B$3.84B$9.41B$18.62B
    Total liabilities$33.94B$33.51B$34.39B$37.53B$39.17B$39.55B$36.59B$36.45B$45.15B$31.95B
    Short-term debt$3.03B$1.50B$1.08B$2.25B$754.00M$220.00M$1.48B$207.00M$714.00M$1.32B
    Long-term debt$9.90B$12.63B$13.60B$14.52B$17.30B$18.53B$16.66B$19.36B$27.21B$20.68B
    Shareholder equity$52.13B$47.66B$38.60B$36.69B$35.80B$32.78B$31.09B$30.52B$30.90B$20.54B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$108.25B$109.22B$110.43B$86.71B$84.18B$84.00B$81.45B$81.41B$74.36B$73.02B$72.47B$73.21B
    Total liabilities$56.62B$57.45B$57.73B$33.94B$32.92B$33.17B$32.38B$33.51B$34.33B$33.46B$33.42B$34.39B
    Cash and equivalents$4.05B$5.10B$6.80B$8.52B$7.51B$6.95B$6.53B$7.62B$7.56B$6.99B$6.28B$6.90B
    Shareholder equity$51.03B$51.11B$52.06B$52.13B$50.95B$50.56B$48.81B$47.66B$39.80B$39.32B$38.81B$38.60B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 77.2% of operating cash flow. Dividends and share repurchases together came to 67.8% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$9.57B$8.56B$7.26B$9.58B$10.53B$7.90B$6.14B$6.30B$5.57B$3.20B
    Capital expenditures$2.17B$2.21B$2.20B$1.78B$1.89B$2.18B$1.64B$1.39B$1.14B$1.12B
    Free cash flow$7.39B$6.35B$5.06B$7.80B$8.65B$5.72B$4.50B$4.91B$4.43B$2.08B
    Dividends paid$4.12B$3.84B$3.56B$3.31B$3.20B$2.56B$2.27B$1.97B$1.85B$1.54B
    Share repurchases$893.00M$1.29B$1.23B$3.79B$2.30B$403.00M$718.00M$238.00M$117.00M$522.00M
    Investing cash flow-$2.42B-$2.34B-$3.13B-$1.74B-$2.01B-$2.21B-$1.81B-$1.36B-$9.62B-$248.00M
    Financing cash flow-$6.31B-$5.40B-$7.09B-$7.64B-$5.49B-$2.78B-$4.29B-$10.39B-$5.28B$11.15B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$1.74B$2.49B$1.31B$3.31B$2.79B$2.05B$1.42B$2.87B$2.71B$1.96B$1.02B$3.04B
    Capital expenditures$513.00M$497.00M$399.00M$689.00M$496.00M$502.00M$484.00M$720.00M$556.00M$533.00M$398.00M$755.00M
    Free cash flow$1.22B$1.99B$916.00M$2.63B$2.29B$1.54B$933.00M$2.15B$2.15B$1.43B$627.00M$2.28B
    Last 12 quarters

    Frequently Asked Questions About ABT

    What is Abbott Laboratories' annual revenue?

    Abbott Laboratories reported revenue of $44.33B for the fiscal year ended Dec 31, 2025.

    How fast is Abbott Laboratories' revenue growing?

    Revenue was up 5.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 0.5%.

    Is Abbott Laboratories profitable?

    Yes. Abbott Laboratories reported net income of $6.52B for the fiscal year ended Dec 31, 2025, with a net margin of 14.7%.

    How much free cash flow does ABT generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $9.57B minus capital expenditures of $2.17B produced free cash flow of $7.39B.

    How much debt does Abbott Laboratories have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $9.90B, short-term debt of $3.03B and cash and equivalents of $8.52B.